GAITHERSBURG, MD, Vector BioMed, a biomanufacturing company specializing in the manufacture of lentiviral vectors, announced its launch and first financing round.
The round was led by Viking Global Investors and Casdin Capital. The funds will support the acceleration of commercial operations to provide rapid access to high-quality lentiviral vectors for pre-clinical development, clinical trials, and commercialization.
Vector BioMed is a state-of-the-art vector contract development and manufacturing organization (CDMO) specializing in best-in-class lentiviral vectors to increase efficiencies in clinical development and commercialization of cell and gene therapies. Vector BioMed's services include turn-key solutions for vector design, vector optimization, pre-clinical manufacturing, validation, and GMP manufacturing to address the biotechnology industry's current vector supply bottleneck by providing high-titer lentiviral vectors from bench to clinic to commercialization. Vector BioMed is the first company to be originated by Caring Cross, a 501(c)(3) non-profit dedicated to accelerating the development of advanced medicines and enabling access to cures for all patients.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about